Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016| Dave Fornell

Update for LAA Occluder Technology News and Trends

Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the left atrial appendage (LAA). The standard of care is use of warfarin or newer anticoagulation therapy agents, but there has been growing interest in eliminating the need for these drugs and their associated increased bleeding risks by closing off the LAA to prevent clot formation. Device therapy now exists for both open surgical and transcatheter LAA occlusion. 

Below are links to recent DAIC articles that offer an update on this cardiovascular technology area:

 

Occluding the Left Atrial Appendage (LAA)

VIDEO - Post-FDA Approval Experience of LAA Occluders at ACC.16

FDA Approves Pivotal Trial for St, Jude's Amulet LAA Occluder

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Societies Issue Recommendations for Left Atrial Appendage Occlusion

Biosense Webster Acquires Coherex Medical LAA Occluder Technology

Medicare Will Cover Watchman Left Atrial Appendage Closure Device

AtriCure Receives FDA Clearance for New AtriClip Device

New Study Demonstrates Cost-Effectiveness of Watchman Device

Boston Scientific Receives CE Mark For Next-generation Watchman FLX LAA Closure Device

FDA Announces Safety Issues With Lariat Left Atrial Appendage (LAA) Closure Device

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

AtriCure Receives CE Mark for AtriClip PRO2 Device

New Data Supports St. Jude Medical FFR and LAA Closure Technology

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

SentreHEART Receives FDA Approval for AMAZE Trial of Lariat Suture Delivery Device

Valley Hospital Begins Enrollment for aMAZE Trial

AtriCure Enrolls First Patient in ATLAS Study

Role of Interventional Echocardiography in Transcatheter Structural Heart Procedures

 

Related Content

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
Overlay Init